{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-22-003072","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.063083+00:00","generated_at":"2026-06-24T00:19:52.327029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chemomab Q2 net loss $6.2M, cash $51.8M; NASH topline due by year-end","bullets":["Net loss $6.2M ($0.03/share) for Q2 2022 vs $2.8M loss in Q2 2021; R&D expense rose to $2.9M from $1.3M.","Cash, equivalents and deposits $51.8M at June 30; runway expected through end of 2023.","Phase 2 NASH trial completed treatment; topline safety and activity data expected before year-end 2022.","Phase 2 PSC trial expanded to 93 patients across three dose cohorts; topline data anticipated H2 2024.","Appointed Jill Quigley to board, Ilan Vaknin as VP R&D, and Christina Crater as VP Clinical Development."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-22-003072","json":"https://secwatch.observer/filing/0001178913-22-003072.json","markdown":"https://secwatch.observer/filing/0001178913-22-003072.md","text":"https://secwatch.observer/filing/0001178913-22-003072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322003072/0001178913-22-003072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322003072/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:19:52.327029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}